Polaris Partners

Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.

FIRE1 is an Irish-based company specializing in the development of innovative therapeutic devices. Its flagship product is a remote monitoring system designed to enhance heart failure patients' lives by providing real-time data to healthcare providers, facilitating early detection and proactive interventions.

Candesant Biomedical, Incorporated is a medical device company focused on developing innovative solutions for excessive sweating and hyperhidrosis. Founded in 2015 and based in San Francisco, California, the company offers a proprietary device known as CDX-101, which utilizes water-activated technology to target and inactivate active sweat glands without causing discomfort to patients. The technology operates on the principle that alkali metals generate energy upon contact with water, allowing for precise energy delivery to the specific areas where sweat glands are most active. This approach not only aims to reduce excessive sweating but also helps inhibit bacterial growth associated with hyperhidrosis, providing a significant improvement in the quality of life for affected individuals.

Scholar Rock is a biopharmaceutical company dedicated to discovering and developing innovative therapies targeting dysregulated growth factors in disease microenvironments. Its proprietary platform enables the creation of monoclonal antibodies that selectively modulate these proteins at the cellular level, potentially avoiding historical challenges associated with inhibiting growth factors. The company's lead product candidate, SRK-015, is a selective inhibitor of myostatin activation for treating neuromuscular disorders like spinal muscular atrophy.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Thirty Madison is a digital health company specializing in personalized treatments for chronic conditions. It operates platforms like Keeps (hair loss), Cove (migraines), Picnic (allergies), Facet (skin conditions), and Nurx (sexual health). Founded in 2016, it aims to empower individuals with accessible, effective care tailored to their specific needs.

FidoCure develops AI-driven precision medicine for canine cancer. It analyzes data from naturally occurring canine tumors using next-generation sequencing and clinical information to build a proprietary learning database for cancer analysis. The company provides genomic sequencing services and targeted therapy recommendations to veterinarians, enabling personalized treatment plans. By linking veterinary and human oncology, FidoCure advances comparative oncology, aims to improve outcomes for dogs and to inform drug development that benefits both pets and people.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Thirty Madison is a digital health company specializing in personalized treatments for chronic conditions. It operates platforms like Keeps (hair loss), Cove (migraines), Picnic (allergies), Facet (skin conditions), and Nurx (sexual health). Founded in 2016, it aims to empower individuals with accessible, effective care tailored to their specific needs.

Umbulizer is a manufacturer of low-cost, portable breathing devices aimed at reducing patient fatalities, particularly in resource-limited settings. The company's flagship product, UMV-001, is designed to deliver continuous ventilation, making it suitable for emergency situations where traditional ventilators may not be available. Their devices are user-friendly and can be wirelessly monitored, enabling medical practitioners to effectively use them in critical care scenarios. By addressing the urgent demand for life-saving ventilators, Umbulizer contributes significantly to improving patient outcomes in challenging healthcare environments.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Ajax Health is a venture capital firm dedicated to the healthcare sector. It invests across stages in medical devices, medtech, healthcare services, digital health, biotechnology and healthcare information technology, aiming to advance innovative solutions that address major healthcare challenges. Founded in 2017, the firm is headquartered in Menlo Park, California, with an additional office in New York City. Ajax Health seeks to accelerate medical innovation through capital and capabilities to support portfolio companies.

Ajax Health is a venture capital firm dedicated to the healthcare sector. It invests across stages in medical devices, medtech, healthcare services, digital health, biotechnology and healthcare information technology, aiming to advance innovative solutions that address major healthcare challenges. Founded in 2017, the firm is headquartered in Menlo Park, California, with an additional office in New York City. Ajax Health seeks to accelerate medical innovation through capital and capabilities to support portfolio companies.

Africa Healthcare Network is a provider of dialysis services across Sub‑Saharan Africa, operating the region’s first dialysis chain in Rwanda, Tanzania and Kenya. The company supplies high‑quality, life‑saving dialysis for acute kidney injury and end‑stage renal disease at affordable prices. It addresses the scarcity of dialysis centers by training local professionals, sourcing low‑cost consumables, and implementing efficient operations. By expanding access to reliable treatment, the network reduces travel burdens and costs for patients, improving outcomes while maintaining financial sustainability.

Candesant Biomedical, Incorporated is a medical device company focused on developing innovative solutions for excessive sweating and hyperhidrosis. Founded in 2015 and based in San Francisco, California, the company offers a proprietary device known as CDX-101, which utilizes water-activated technology to target and inactivate active sweat glands without causing discomfort to patients. The technology operates on the principle that alkali metals generate energy upon contact with water, allowing for precise energy delivery to the specific areas where sweat glands are most active. This approach not only aims to reduce excessive sweating but also helps inhibit bacterial growth associated with hyperhidrosis, providing a significant improvement in the quality of life for affected individuals.

Gauss Surgical, Inc. is a medical technology company that specializes in real-time blood monitoring solutions to enhance patient outcomes in surgical and obstetric settings. Founded in 2011 and headquartered in Los Altos, California, Gauss Surgical develops the Triton system, which includes various models suited for different medical needs. Triton assists healthcare professionals in monitoring and estimating blood loss during procedures, allowing for timely intervention in cases of hemorrhage. The system offers objective metrics for blood loss, thereby facilitating better clinical decision-making regarding transfusions. Serving the healthcare sector primarily in the United States, Gauss Surgical's products are designed to integrate seamlessly into existing medical practices, using sophisticated algorithms and HIPAA-compliant technology to deliver accurate monitoring in real time.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Ajax Health is a venture capital firm dedicated to the healthcare sector. It invests across stages in medical devices, medtech, healthcare services, digital health, biotechnology and healthcare information technology, aiming to advance innovative solutions that address major healthcare challenges. Founded in 2017, the firm is headquartered in Menlo Park, California, with an additional office in New York City. Ajax Health seeks to accelerate medical innovation through capital and capabilities to support portfolio companies.

Scholar Rock is a biopharmaceutical company dedicated to discovering and developing innovative therapies targeting dysregulated growth factors in disease microenvironments. Its proprietary platform enables the creation of monoclonal antibodies that selectively modulate these proteins at the cellular level, potentially avoiding historical challenges associated with inhibiting growth factors. The company's lead product candidate, SRK-015, is a selective inhibitor of myostatin activation for treating neuromuscular disorders like spinal muscular atrophy.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

YourBio Health specializes in innovative blood sampling technologies. Their flagship product, Seventh Sense On Vivo™ platform, enables safe and painless diagnostic testing using proprietary Touch Activated Phlebotomy™ (TAP™) technology. This single-step process can be integrated with various diagnostic assays for rapid results, improving patient experience and accessibility to critical healthcare information.

Africa Healthcare Network is a provider of dialysis services across Sub‑Saharan Africa, operating the region’s first dialysis chain in Rwanda, Tanzania and Kenya. The company supplies high‑quality, life‑saving dialysis for acute kidney injury and end‑stage renal disease at affordable prices. It addresses the scarcity of dialysis centers by training local professionals, sourcing low‑cost consumables, and implementing efficient operations. By expanding access to reliable treatment, the network reduces travel burdens and costs for patients, improving outcomes while maintaining financial sustainability.

Founded in 2014, Sofregen Medical specializes in developing silk protein-based biomaterials for use in aesthetic procedures and surgeries. The company aims to enhance soft tissue regeneration, restoring function and cosmetic appearance for medical and aesthetic patients worldwide.

Scholar Rock is a biopharmaceutical company dedicated to discovering and developing innovative therapies targeting dysregulated growth factors in disease microenvironments. Its proprietary platform enables the creation of monoclonal antibodies that selectively modulate these proteins at the cellular level, potentially avoiding historical challenges associated with inhibiting growth factors. The company's lead product candidate, SRK-015, is a selective inhibitor of myostatin activation for treating neuromuscular disorders like spinal muscular atrophy.

Olivo Laboratories LLC is a startup focused on advancing dermatology through innovative biomaterials technology. The company has developed proprietary skin-conforming polymer materials, including its pioneering XPLTM “Second Skin” technology. This technology utilizes a tunable polysiloxane-based material that closely mimics youthful skin, offering various customizable properties such as elasticity, breathability, invisibility, and water resistance. Olivo Laboratories aims to provide dermatologists and physicians with effective solutions for treating both medical and cosmetic skin-related conditions.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Pulmatrix is a clinical-stage biopharmaceutical company developing inhaled therapies to address serious pulmonary diseases using its patented iSPERSE technology. Its pipeline focuses on Pulmazole, an inhaled anti-fungal for allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor for obstructive lung diseases like asthma and COPD.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Arsia Therapeutics’ mission is to improve access to these life-saving drugs, make them more patient-friendly, and reduce healthcare costs by enabling subcutaneous delivery in non-hospital settings. Biopharmaceuticals are much larger and more fragile than traditional small-molecule drugs. Due to their size, large doses of biologics are often required; and because of their fragility, these drugs must be administered by injection instead of orally. Biologics become unstable and extremely viscous at the high concentrations required for traditional low-volume injections. Consequently, they are frequently administered as high-volume, slow intravenous infusions in a hospital setting. From a patient perspective, receiving treatment via subcutaneous administration can be preferable to intravenous infusion. Subcutaneous administration removes the need for invasive IV ports. Administration at home eliminates time-intensive and expensive hospital visits. Achieving high doses of biologics in a volume suitable for subcutaneous administration presents significant formulation challenges. The major limiting factor is viscosity, which arises when biomolecules are formulated at high concentration. Arsia’s mission is to produce high-concentration biopharmaceutical products with low viscosity, suitable for small-volume subcutaneous injection. Our proprietary platform technology reduces the viscosity of biologics through the addition of inactive ingredients (excipients). Because Arsia’s technology works at the formulation stage, the molecular structure of the drug itself is not affected. Arsia’s technology provides i) a formulation solution for new products in development that have viscosity challenges, ii) a life-cycle management strategy for existing products and iii) a way to differentiate those products from others on the market. For more information on partnering with Arsia, please contact us.

Scholar Rock is a biopharmaceutical company dedicated to discovering and developing innovative therapies targeting dysregulated growth factors in disease microenvironments. Its proprietary platform enables the creation of monoclonal antibodies that selectively modulate these proteins at the cellular level, potentially avoiding historical challenges associated with inhibiting growth factors. The company's lead product candidate, SRK-015, is a selective inhibitor of myostatin activation for treating neuromuscular disorders like spinal muscular atrophy.

YourBio Health specializes in innovative blood sampling technologies. Their flagship product, Seventh Sense On Vivo™ platform, enables safe and painless diagnostic testing using proprietary Touch Activated Phlebotomy™ (TAP™) technology. This single-step process can be integrated with various diagnostic assays for rapid results, improving patient experience and accessibility to critical healthcare information.

WellAir Group Limited, founded in 2012 and based in Dublin, Ireland, specializes in designing and manufacturing portable air disinfection units and HVAC air purification devices. The company aims to improve indoor air quality by eliminating airborne pollutants and pathogens, including viruses, bacteria, allergens, and mold. Its products, marketed under the Novaerus and Plasma-Air brands, serve a variety of sectors such as healthcare, senior living, education, and industry. WellAir's offerings include medical-grade air disinfection units that deactivate airborne pathogens and neutralize volatile organic compounds, as well as HVAC systems utilizing plasma-generated bipolar ionization to reduce particulate matter and odors. Additionally, WellAir develops sensors and a web-based monitoring portal that tracks outdoor air pollution and other environmental factors, contributing to safer indoor environments and promoting public health.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

YourBio Health specializes in innovative blood sampling technologies. Their flagship product, Seventh Sense On Vivo™ platform, enables safe and painless diagnostic testing using proprietary Touch Activated Phlebotomy™ (TAP™) technology. This single-step process can be integrated with various diagnostic assays for rapid results, improving patient experience and accessibility to critical healthcare information.

Vets First Choice provides veterinary practices with an online pharmacy and home delivery services. It partners with veterinarians to create insight into gaps in patient care and offer professionalized pro-active prescription management to drive client engagement and improve compliance. The company was founded by Ben Shaw in 2010 and is based in Portland, Maine.

Infinite Power Solutions, Inc. (IPS) is a clean-technology company based in the United States, specializing in the development, marketing, and manufacturing of solid-state, rechargeable thin-film micro-energy storage devices. Founded in 2001 and headquartered in the Denver, Colorado area, the company is recognized as a leader in the production of thin-film micro-energy cells, commonly referred to as thin-film batteries. IPS has established the world's first volume manufacturing facility dedicated to these innovative products and has begun pre-production activities to meet the increasing demand across various sectors. Its micro-energy storage solutions are utilized in a wide range of applications, including military, aerospace, wireless sensors, active RFID, powered smart cards, implantable medical devices, consumer electronics, and automotive markets.

Apnex Medical, Inc. manufactures and markets medical devices such as implants for the treatment of obstructive sleep apnea. Apnex Medical, Inc. was incorporated in 2006 and is based in Saint Paul, Minnesota.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Pulmatrix is a clinical-stage biopharmaceutical company developing inhaled therapies to address serious pulmonary diseases using its patented iSPERSE technology. Its pipeline focuses on Pulmazole, an inhaled anti-fungal for allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor for obstructive lung diseases like asthma and COPD.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Ella Health is a women's wellness provider headquartered in San Francisco, California, with multiple centers across the United States. The company focuses on delivering healthcare services tailored specifically for women, including advanced 3D mammography, which enhances cancer detection and minimizes false positives compared to traditional 2D imaging. Additionally, Ella Health offers physical therapy programs designed to address the unique needs of women at various stages of life. By combining innovative technology with compassionate care and aesthetically pleasing environments, Ella Health aims to create a welcoming atmosphere that helps women feel more comfortable and empowered in managing their health.

YourBio Health specializes in innovative blood sampling technologies. Their flagship product, Seventh Sense On Vivo™ platform, enables safe and painless diagnostic testing using proprietary Touch Activated Phlebotomy™ (TAP™) technology. This single-step process can be integrated with various diagnostic assays for rapid results, improving patient experience and accessibility to critical healthcare information.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.

Follica, Inc. is a Boston-based company focused on developing innovative therapies for hair loss in adults. Established in 2005, Follica specializes in a proprietary treatment system that includes an in-office device designed to disrupt the skin and stimulate the creation of new hair follicles. Additionally, the company offers an at-home treatment system that delivers therapeutic compounds directly to the scalp, facilitating a daily hair care routine. Follica's approach targets conditions related to hair follicles, addressing a market that exceeds $10 billion annually and is characterized by a lack of effective solutions. The company's regenerative biology-based technology aims to not only create new hair follicles but also to thicken existing hair, providing clinicians with effective treatment options for their patients.

SiOnyx, Inc. is a company based in Beverly, Massachusetts, that specializes in advanced semiconductor technology focusing on shallow junction photonics. Founded in 2005, SiOnyx enhances the infrared sensitivity of silicon-based photonics, leading to significant improvements in light-sensing devices. The company develops ultra-low-light image sensors and night vision camera systems that cater to a diverse range of applications, including security, defense, consumer electronics, industrial, medical, and automotive sectors. Its product offerings include XQE CMOS image sensors, which enable functionalities such as night vision, biometrics, and eye-tracking, as well as HD action video cameras. SiOnyx is recognized for making digital night vision technology more accessible, thereby enhancing optoelectronic response in both visible and near-infrared regions.

Phreesia is a technology company focused on enhancing patient care experiences. It replaces traditional clipboard-based check-in processes with secure, wireless touchscreen devices that collect patient information compatible with electronic medical records. Phreesia improves operational efficiency and patient satisfaction by automating administrative tasks, providing relevant health education, and facilitating seamless data transfer between patients' previous visits.

Respicardia, Inc. is a medical technology company based in Minnetonka, Minnesota, focused on enhancing respiratory rhythm management and cardiovascular health for heart failure patients. Founded in 2006, the company develops and manufactures innovative implantable stimulation therapy solutions, notably the remede System. This device is designed to restore normal breathing patterns during sleep for individuals suffering from central sleep apnea. Respicardia aims to improve the lives of these patients through safe and effective neurostimulation therapies that stimulate the phrenic nerve, thereby addressing critical needs in respiratory and cardiovascular health.

Infinite Power Solutions, Inc. (IPS) is a clean-technology company based in the United States, specializing in the development, marketing, and manufacturing of solid-state, rechargeable thin-film micro-energy storage devices. Founded in 2001 and headquartered in the Denver, Colorado area, the company is recognized as a leader in the production of thin-film micro-energy cells, commonly referred to as thin-film batteries. IPS has established the world's first volume manufacturing facility dedicated to these innovative products and has begun pre-production activities to meet the increasing demand across various sectors. Its micro-energy storage solutions are utilized in a wide range of applications, including military, aerospace, wireless sensors, active RFID, powered smart cards, implantable medical devices, consumer electronics, and automotive markets.

Follica, Inc. is a Boston-based company focused on developing innovative therapies for hair loss in adults. Established in 2005, Follica specializes in a proprietary treatment system that includes an in-office device designed to disrupt the skin and stimulate the creation of new hair follicles. Additionally, the company offers an at-home treatment system that delivers therapeutic compounds directly to the scalp, facilitating a daily hair care routine. Follica's approach targets conditions related to hair follicles, addressing a market that exceeds $10 billion annually and is characterized by a lack of effective solutions. The company's regenerative biology-based technology aims to not only create new hair follicles but also to thicken existing hair, providing clinicians with effective treatment options for their patients.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Phreesia is a technology company focused on enhancing patient care experiences. It replaces traditional clipboard-based check-in processes with secure, wireless touchscreen devices that collect patient information compatible with electronic medical records. Phreesia improves operational efficiency and patient satisfaction by automating administrative tasks, providing relevant health education, and facilitating seamless data transfer between patients' previous visits.

Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

MicroCHIPS Biotech, Inc. specializes in developing a microchip-based implant designed for drug delivery applications across various therapeutic areas, including osteoporosis, diabetes, multiple sclerosis, women’s contraception, and pain management. This innovative implant can store and release precise doses of medication over extended periods, offering an alternative to traditional therapies that rely on frequent injections. The implant is surgically placed under the skin during a minimally invasive procedure and can be wirelessly activated or deactivated by healthcare providers or patients. Additionally, the device allows for real-time adjustments to the drug dosage and frequency, catering to the specific needs of each patient. Established in 1999 and headquartered in Lexington, Massachusetts, MicroCHIPS operates as a subsidiary of Daré Bioscience, Inc.

Apnex Medical, Inc. manufactures and markets medical devices such as implants for the treatment of obstructive sleep apnea. Apnex Medical, Inc. was incorporated in 2006 and is based in Saint Paul, Minnesota.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Pulmatrix is a clinical-stage biopharmaceutical company developing inhaled therapies to address serious pulmonary diseases using its patented iSPERSE technology. Its pipeline focuses on Pulmazole, an inhaled anti-fungal for allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor for obstructive lung diseases like asthma and COPD.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Pulmatrix is a clinical-stage biopharmaceutical company developing inhaled therapies to address serious pulmonary diseases using its patented iSPERSE technology. Its pipeline focuses on Pulmazole, an inhaled anti-fungal for allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor for obstructive lung diseases like asthma and COPD.

GI Dynamics, Inc. is a medical device company that specializes in designing, developing, and manufacturing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company’s primary product, EndoBarrier, is aimed at helping patients manage their condition and reduce obesity without the need for surgical intervention. GI Dynamics serves healthcare providers and third-party distributors, selling its products mainly in Europe, the Middle East, the Asia Pacific, and South America. Founded in 2003, the company is headquartered in Lexington, Massachusetts.

Phreesia is a technology company focused on enhancing patient care experiences. It replaces traditional clipboard-based check-in processes with secure, wireless touchscreen devices that collect patient information compatible with electronic medical records. Phreesia improves operational efficiency and patient satisfaction by automating administrative tasks, providing relevant health education, and facilitating seamless data transfer between patients' previous visits.

WaveRx, Inc. went out of business. WaveRx, Inc. operates as a medical device company that develops technologies and products for dermatological disorders of the nail and skin. WaveRx, Inc. was formerly known as ID Wave Systems and changed its name to WaveRx, Inc. in October 2005. The company was incorporated in 2004 and is based in Waltham, Massachusetts.

Infinite Power Solutions, Inc. (IPS) is a clean-technology company based in the United States, specializing in the development, marketing, and manufacturing of solid-state, rechargeable thin-film micro-energy storage devices. Founded in 2001 and headquartered in the Denver, Colorado area, the company is recognized as a leader in the production of thin-film micro-energy cells, commonly referred to as thin-film batteries. IPS has established the world's first volume manufacturing facility dedicated to these innovative products and has begun pre-production activities to meet the increasing demand across various sectors. Its micro-energy storage solutions are utilized in a wide range of applications, including military, aerospace, wireless sensors, active RFID, powered smart cards, implantable medical devices, consumer electronics, and automotive markets.

Respicardia, Inc. is a medical technology company based in Minnetonka, Minnesota, focused on enhancing respiratory rhythm management and cardiovascular health for heart failure patients. Founded in 2006, the company develops and manufactures innovative implantable stimulation therapy solutions, notably the remede System. This device is designed to restore normal breathing patterns during sleep for individuals suffering from central sleep apnea. Respicardia aims to improve the lives of these patients through safe and effective neurostimulation therapies that stimulate the phrenic nerve, thereby addressing critical needs in respiratory and cardiovascular health.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

Follica, Inc. is a Boston-based company focused on developing innovative therapies for hair loss in adults. Established in 2005, Follica specializes in a proprietary treatment system that includes an in-office device designed to disrupt the skin and stimulate the creation of new hair follicles. Additionally, the company offers an at-home treatment system that delivers therapeutic compounds directly to the scalp, facilitating a daily hair care routine. Follica's approach targets conditions related to hair follicles, addressing a market that exceeds $10 billion annually and is characterized by a lack of effective solutions. The company's regenerative biology-based technology aims to not only create new hair follicles but also to thicken existing hair, providing clinicians with effective treatment options for their patients.

PartsSource, Inc. is a provider of biomedical replacement parts and procurement solutions to healthcare facilities, including hospitals and imaging centers, both in the United States and internationally. Founded in 2001 and headquartered in Aurora, Ohio, the company offers a wide range of products, such as batteries, infusion pumps, patient monitors, and MRI parts, tailored for biomedical equipment technicians and clinical engineers. PartsSource also features ePartsFinder, a proprietary technology platform that streamlines the ordering and management of medical repair parts, enhancing operational efficiencies and reducing costs through its innovative SmartPrice technology. By automating the procurement process, PartsSource aims to improve the overall healthcare supply chain and support effective healthcare technology management.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Phreesia is a technology company focused on enhancing patient care experiences. It replaces traditional clipboard-based check-in processes with secure, wireless touchscreen devices that collect patient information compatible with electronic medical records. Phreesia improves operational efficiency and patient satisfaction by automating administrative tasks, providing relevant health education, and facilitating seamless data transfer between patients' previous visits.

Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

Apnex Medical, Inc. manufactures and markets medical devices such as implants for the treatment of obstructive sleep apnea. Apnex Medical, Inc. was incorporated in 2006 and is based in Saint Paul, Minnesota.

Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.

Infinite Power Solutions, Inc. (IPS) is a clean-technology company based in the United States, specializing in the development, marketing, and manufacturing of solid-state, rechargeable thin-film micro-energy storage devices. Founded in 2001 and headquartered in the Denver, Colorado area, the company is recognized as a leader in the production of thin-film micro-energy cells, commonly referred to as thin-film batteries. IPS has established the world's first volume manufacturing facility dedicated to these innovative products and has begun pre-production activities to meet the increasing demand across various sectors. Its micro-energy storage solutions are utilized in a wide range of applications, including military, aerospace, wireless sensors, active RFID, powered smart cards, implantable medical devices, consumer electronics, and automotive markets.

BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.

Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

Archus Orthopedics is focused on the development of implants to treat a variety of spine disorders that result from degenerative changes in the facet joints. Archus Orthopedics offers Total Facet Arthroplasty System, a spinal implant that is designed for patients suffering from lumbar spinal stenosis. Archus Orthopedics was acquired by Facet Solutions in November 2009. Archus Orthopedics was founded in 2001 and is based in Redmond, Washington.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Asthmatx is a medical device company based in Mountain View, California, founded in 2003 and now operating as a subsidiary of Boston Scientific. The company specializes in developing and commercializing therapeutic treatments for asthma. Asthmatx has created a technology that delivers controlled thermal energy to the airways of adult patients to reduce airway smooth muscle mass through a procedure known as Bronchial Thermoplasty. Their flagship product is the Alair System, an interventional medical device designed for bronchoscopic treatment of moderate to severe asthma.

Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

Prospex Medical was a medical device incubator based in Stillwater, Minnesota, dedicated to innovating and developing novel medical technologies. The company focused on both regulated medical devices and quasi-consumer medical products, exploring various opportunities within the healthcare market. Through a comprehensive approach involving market identification, clinical and technical research, physician collaboration, and intellectual property generation, Prospex Medical successfully created and spun out two companies: BridgePoint Medical and Apnex Medical. Although now dormant, Prospex Medical played a significant role in advancing healthcare innovation by fostering new solutions and technologies.

Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. It focuses on creating innovative miniature implants and medical devices to improve patient monitoring. The company's flagship products include RemonCHF, which is designed to monitor the hemodynamic status of patients suffering from congestive heart failure, and RemonAAA, a device that tracks pressure levels following endograft procedures in patients with abdominal aortic aneurysms. Through its advanced monitoring solutions, Remon Medical Technologies aims to enhance patient care and outcomes in critical healthcare scenarios.

Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. It focuses on creating innovative miniature implants and medical devices to improve patient monitoring. The company's flagship products include RemonCHF, which is designed to monitor the hemodynamic status of patients suffering from congestive heart failure, and RemonAAA, a device that tracks pressure levels following endograft procedures in patients with abdominal aortic aneurysms. Through its advanced monitoring solutions, Remon Medical Technologies aims to enhance patient care and outcomes in critical healthcare scenarios.

GI Dynamics, Inc. is a medical device company that specializes in designing, developing, and manufacturing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company’s primary product, EndoBarrier, is aimed at helping patients manage their condition and reduce obesity without the need for surgical intervention. GI Dynamics serves healthcare providers and third-party distributors, selling its products mainly in Europe, the Middle East, the Asia Pacific, and South America. Founded in 2003, the company is headquartered in Lexington, Massachusetts.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Archus Orthopedics is focused on the development of implants to treat a variety of spine disorders that result from degenerative changes in the facet joints. Archus Orthopedics offers Total Facet Arthroplasty System, a spinal implant that is designed for patients suffering from lumbar spinal stenosis. Archus Orthopedics was acquired by Facet Solutions in November 2009. Archus Orthopedics was founded in 2001 and is based in Redmond, Washington.

Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company focuses on addressing rare genetic diseases, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system/ocular disorders. Its marketed products include ONPATTRO, a treatment for hereditary transthyretin-mediated amyloidosis, and GIVLAARI, which targets acute hepatic porphyria. Alnylam’s pipeline includes investigational therapies such as givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, and vutrisiran for transthyretin amyloidosis. The company has established strategic alliances with notable partners like Sanofi Genzyme and Regeneron Pharmaceuticals, and it collaborates with Vir Biotechnology on RNAi therapeutics for coronavirus infections. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is at the forefront of transforming RNAi science into innovative medicines to improve patient outcomes.

GI Dynamics, Inc. is a medical device company that specializes in designing, developing, and manufacturing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company’s primary product, EndoBarrier, is aimed at helping patients manage their condition and reduce obesity without the need for surgical intervention. GI Dynamics serves healthcare providers and third-party distributors, selling its products mainly in Europe, the Middle East, the Asia Pacific, and South America. Founded in 2003, the company is headquartered in Lexington, Massachusetts.

Acusphere, Inc. is a specialty pharmaceutical company based in Watertown, Massachusetts, focused on developing and commercializing cardiovascular drugs. The company's primary product, Imagify, is an injectable suspension of perflubutane polymer microspheres designed to evaluate myocardial perfusion and detect coronary artery disease. Acusphere is actively seeking regulatory approval for Imagify in Europe and is negotiating with the FDA regarding additional trials necessary for U.S. approval. Founded in 1993 and originally named Polymers For Medicine, Inc., Acusphere has also initiated clinical development for other drugs utilizing its proprietary microparticle technology, including AI-525 for acute pain, AI-850 for oncology, and AI-128 for asthma. The company’s technology allows for the reformulation of hydrophobic drugs and the development of sustained release formulations, showcasing its potential to create a diverse range of new pharmaceutical products.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Advion is a global company founded in 1993 and headquartered in New York, specializing in systems and consumables for life science research. It provides a range of biochemistry analysis equipment, including microfluidic devices and mass spectrometry products aimed at supporting various sectors such as biopharmaceuticals, academic and government research, and industrial chemistry. Advion’s offerings include purpose-built mass spectrometers, nanoelectrospray ionization sources, and flow-chemistry synthesis systems, catering to the needs of pharmaceutical companies, research agencies, and universities worldwide.

MedVantx, headquartered in San Diego, California, is a consumer medication management and delivery company that aims to reduce healthcare costs and improve access to information for patients, healthcare providers, payors, employers, and manufacturers. The company operates a state-of-the-art mail order pharmacy located in Sioux Falls, South Dakota, which is licensed to serve all 50 states. This facility has been upgraded to meet over 200 current Good Manufacturing Practice (cGMP) quality standards and is equipped to handle pharmaceuticals requiring Cold Chain processing. MedVantx has developed a direct-to-patient platform that connects pharmaceutical manufacturers with patients, streamlining delivery processes and enhancing user experience while minimizing costs. In 2009, MedVantx was recognized by Inc. Magazine as the fastest growing privately held healthcare company in the United States.

Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. It focuses on creating innovative miniature implants and medical devices to improve patient monitoring. The company's flagship products include RemonCHF, which is designed to monitor the hemodynamic status of patients suffering from congestive heart failure, and RemonAAA, a device that tracks pressure levels following endograft procedures in patients with abdominal aortic aneurysms. Through its advanced monitoring solutions, Remon Medical Technologies aims to enhance patient care and outcomes in critical healthcare scenarios.